Hydroxychloroquine offers « no beneficial effect » in hospitalized patients with COVID-19, researchers at the University of Oxford In England announced Friday.
June 5 (UPI) — Hydroxychloroquine offers « no beneficial effect » in hospitalized patients with COVID-19, researchers at the University of Oxford In England announced Friday.
Just over one in four patients who received the anti-malaria drug died within 28 days of starting treatment, while slightly less than one in four of those who received usual care — basically supportive management of heart and lung symptoms — died within that time frame, researchers heading up the RECOVERY trial said.
The findings are based on an analysis of data from 80 percent of the study participants, they said.
« These data convincingly rule out any meaningful mortality benefit of hydroxychloroquine in patients hospitalized with COVID-19, » they said in a statement. « Full results will be made available as soon as possible, » they said.
« There has been huge speculation and uncertainty about the role of hydroxychloroquine as a treatment for COVID-19, but an absence of reliable information from large randomized trials, » Dr.
